Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.
To evaluate the potential value of using a serological assay to quantitate the hepatitis C virus core antigen (HCV-Ag) when monitoring patients with chronic hepatitis C being treated with direct-acting antivirals (DAAs).Ninety-six patients treated with DAAs, either alone (91) or in combination with...
Main Authors: | Elisabetta Loggi, Silvia Galli, Giovanni Vitale, Roberto Di Donato, Ranka Vukotic, Elena Grandini, Marzia Margotti, Valeria Guarneri, Giuliano Furlini, Claudio Galli, Maria Carla Re, Pietro Andreone |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5681287?pdf=render |
Similar Items
-
Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment
by: Stefano Gitto, et al.
Published: (2018-01-01) -
Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin
by: Fabio Conti, et al.
Published: (2014-03-01) -
Chlamydophila pneumoniae serological epidemiology
by: Salvatore Pignanelli, et al.
Published: (2010-06-01) -
Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels.
by: Elisabetta Loggi, et al.
Published: (2013-01-01) -
VALUTAZIONE QUANTITATIVA DELL’HBsAg NELL’EPATITE CRONICA B
by: G. Furlini, et al.
Published: (2005-09-01)